Cis-platinum in the treatment of advanced or recurrent adenocarcinoma of the ovary. A phase II study of the Gynecologic Oncology Group

Am J Clin Oncol. 1983 Aug;6(4):431-5. doi: 10.1097/00000421-198308000-00008.

Abstract

Thirty-seven patients with advanced or recurrent adenocarcinoma of the ovary no longer amenable to control with surgery, radiation therapy, or higher prior chemotherapy were treated with cis-platinum, 50 mg/m2 intravenously every 3 weeks. Among the 37 patients, three patients had a clinical complete response (8%) and six had a partial response (16%). Twenty-three demonstrated stable disease (62%), while five demonstrated rapidly increasing disease (14%). Median response duration was 5 months and median survival was 10+ months. Responders survived longer than nonresponders (p = 0.01). Adverse effects included leukopenia (26/37), thrombocytopenia (19/37), nausea and vomiting (35/37), and azotemia (19/37). Adverse effects were generally mild to moderate and tolerable. Cis-platinum thus appears to be highly active in the treatment of adenocarcinoma of the ovary at the dose and schedule tested.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Adult
  • Aged
  • Cisplatin / adverse effects
  • Cisplatin / therapeutic use*
  • Drug Evaluation
  • Female
  • Humans
  • Leukocyte Count
  • Leukopenia / chemically induced
  • Middle Aged
  • Nausea / chemically induced
  • Neoplasm Recurrence, Local
  • Ovarian Neoplasms / drug therapy*
  • Thrombocytopenia / chemically induced
  • Vomiting / chemically induced

Substances

  • Cisplatin